High-Efficiency mRNA Production: 887% Enhanced Expression with Ultra-Low Immunogenicity
Discover how CELLSCRIPT™'s dual workflow that combines N1-methyl-pseudouridine (N1meΨ) modification with advanced dsRNA removal achieves high mRNA performance. Our comprehensive study using the INCOGNITO™ T7 mScript™ Complete N1meΨ-mRNA Production System demonstrates a remarkable 887% improvement in protein expression while virtually eliminating immune activation. We show that strategic nucleotide modification paired with Min-Immune™ Gold dsRNA removal creates high-quality, low immunogenic mRNA perfect for downstream therapeutic applications, vaccine development, and gene therapy research. This application note provides detailed methodologies for transforming traditional mRNA synthesis. Download the application note to access the research that's enhancing and setting the standards for best practices in low immunogenicity mRNA production.
Download Now to read the full Application Note.